Bill Abernethy
Member of the Board of Advisors at RarusMed | Beaufort, South Carolina, United States
Engage
candidates 10x faster
Enjoy unlimited access and discover candidates outside of LinkedIn
Trusted by 1.4M users from 76% of Fortune 500 companies
The most accurate data ever
CCPA Compliant
GDPR Compliant
150M
Personal Emails
200M
Work Emails
100M
Direct Dials
250M
Professional Profiles
40M
Company Profiles
Find anyone, anywhere
with ContactOut
today
Making remote or global hires?
Connecting
with key decision-makers? We can help.
- 40 emails / month
- 3 phone numbers / month
- Works on standard LinkedIn only
-
Work emails, personal emails,
mobile numbers
No credit card required
Bill Abernethy serves as a Consultant to the CEO and CMO at Silence Therapeutics plc, where he leverages his extensive experience in commercial biotechnology to drive strategic product development initiatives. With a robust background in the global pharmaceutical market, Bill plays a pivotal role in the advancement of the divesiran project (SLN124), focusing on its potential applications in treating rare genetic diseases. His expertise in orphan drugs and rare diseases positions him uniquely to navigate the complexities of these therapeutic areas, ensuring that innovative solutions reach the patients who need them most.
In his consulting role, Bill emphasizes the importance of engaging with key opinion leaders (KOLs) and patient advocacy groups, fostering collaborative relationships that are essential for early commercial inputs. His strategic insights help Silence Therapeutics align its clinical and regulatory strategies with market needs, enhancing the overall impact of its product pipeline. Bill’s ability to bridge the gap between clinical research and commercialization is critical, as he collaborates closely with internal teams across Clinical, Science, Regulatory, and Investor Relations/Public Relations.
His substantial experience in managing joint ventures with biotechs further enriches his contributions, allowing him to navigate complex partnerships and drive successful collaborations. Bill’s multifaceted skill set in commercialization, product management, and therapeutic area expansion empowers Silence Therapeutics to capitalize on emerging opportunities in the biotechnology landscape, ultimately advancing the mission to deliver innovative therapies for patients with unmet medical needs.
Member of the Board of Advisors at RarusMed in May 2024 to Present
Advisor, Global Market Development at Silence Therapeutics plc in November 2022 to December 2024
Vice President, Global Market Development at Silence Therapeutics plc in August 2019 to February 2021
Senior Vice President Operations at CureDuchenne in February 2018 to February 2019
Vice President and General Manager at Marathon Pharmaceuticals, LLC in October 2016 to May 2017
Executive Director, Global Market Development, Neuromuscular Franchise at BioMarin Pharmaceutical Inc. in April 2015 to September 2016
Vice President, Global Market Development at Prosensa Therapeutics in April 2011 to March 2015
Senior Director, Global Marketing and Strategic Planning, GM Genzyme/PTC Collaboration at Genzyme in August 2008 to November 2010
Senior Director, Special Assignments within Lysosomal Storage Disease Business Unit at Genzyme in April 2007 to August 2008
Director, Global Commercial Strategy, JV with Dyax Corp at Genzyme in January 2005 to January 2007
Director, General Manager, Gaucher Disease at Genzyme in January 2003 to January 2006
Senior Product Manager then Associate Director, Global Marketing, Cerezyme at Genzyme in January 2000 to January 2003
Product Manager, Micardis and Catapres TTS, Cardiovascular Marketing at Boehringer Ingelheim in January 1997 to January 2000
Senior CRA then Product Management at Solvay Pharmaceuticals in January 1989 to January 1997
See more
See less
Biotechnology
Genetics
Pharmaceutical Industry
Orphan diseases/Orphan drugs
Global Marketing
Joint Venture/Collaboration Management
Management
Lifesciences
Drug Product
Product Launch
Cross-functional Team Leadership
Commercialization
Biopharmaceuticals
Product Development
Product Management
Strategy
Therapeutic Areas
Business Development
Clinical Research
Clinical Development
Clinical Trials
Marketing
Market Access
International Marketing
Life Sciences
Drug Development
See more
See less
What is Bill Abernethy email address?
Email Bill Abernethy at [email protected] and [email protected]. This email is the most updated Bill Abernethy email found in 2026.
How to contact Bill Abernethy?
To contact Bill Abernethy send an email to [email protected] or [email protected]. (updated on November 04, 2024)
What company does Bill Abernethy work for?
Bill Abernethy works for RarusMed
What is Bill Abernethy's role at RarusMed?
Bill Abernethy is Member of the Board of Advisors
What is Bill Abernethy's Phone Number?
Bill Abernethy's phone (839) ***-*318
Bill Abernethy Email Addresses
Bill Abernethy Phone Numbers
looking for?
Find personal and work emails for over 250M professionals.
People like Bill Abernethy
Business Manager at Great River Spine and Sport
Fleet & Warehouse Manager at Capital Business Systems, Inc.
Production Associate at Tesla Motors
Gallery Host at Hyatt Place
Senior Quality Assurance Engineer at Kaiser Permanente
Vice President at CORE Construction
Technical Specialist at Sherwin-Williams/ Tennant Coatings/ Florock polymer Flooring
Associate Director, Marketing at Healthline Media
VP of Media Channels & Programming - North America at Red Bull
Deputy Director at Boston Redevelopment Authority/EDIC
Executive Director - Infrastructure & Production Operations at PJM Interconnection
Executive Tax Recruiter at SNI Financial
Executive Assistant at Baxter Fentriss and Company
Executive Vice President & Chief Financial Officer at BELMONT SAVINGS BANK
Training Supervisor at North Carolina Div of Emergency Management
Client Manager at Cigna
Instructor at CrossTown Fitness
Travel, Meetings and Events Manager at Kirkland & Ellis
SVP – Operational Data Analytics & Financial Management at Bank of America
Director of Telecom Operations at American Electric Power
Show more
Show less